Search Result

Isoforms Recommended:	PI3Kα

Results for "

PI3Kα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (23) AMPK (1) Apoptosis (44) ATM/ATR (5) Autophagy (9) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (1) Biochemical Assay Reagents (1) c-Myc (2) Cadherin (1) Casein Kinase (2) Caspase (1) CD3 (1) CDK (7) DNA-PK (7) DNA/RNA Synthesis (1) Dopamine Receptor (3) Drug Intermediate (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (2) Epigenetic Reader Domain (6) ERK (2) GLUT (2) GSK-3 (1) HDAC (7) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HSP (1) Interleukin Related (1) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (2) MAP4K (1) MEK (3) Mitochondrial Metabolism (1) MMP (1) Molecular Glues (1) mTOR (65) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) PAK (1) Paraptosis (1) Parasite (1) PARP (2) PD-1/PD-L1 (1) PERK (3) Phosphatase (2) PI3K (187) PI4K (3) PPAR (1) PROTACs (4) Ras (6) Reactive Oxygen Species (ROS) (3) Reference Standards (16) SARS-CoV (1) Syk (1) VEGFR (1) Virus Protease (1) Wnt (1)
By Research Areas:	Cancer (185) Cardiovascular Disease (1) Infection (9) Inflammation/Immunology (13) Metabolic Disease (7) Neurological Disease (9)

By Targets:

Adenosine Receptor (1)

Akt (23)

AMPK (1)

Apoptosis (44)

ATM/ATR (5)

Autophagy (9)

Bacterial (2)

Bcl-2 Family (1)

Bcr-Abl (1)

Biochemical Assay Reagents (1)

c-Myc (2)

Cadherin (1)

Casein Kinase (2)

Caspase (1)

CD3 (1)

CDK (7)

DNA-PK (7)

DNA/RNA Synthesis (1)

Dopamine Receptor (3)

Drug Intermediate (2)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (2)

Epigenetic Reader Domain (6)

ERK (2)

GLUT (2)

GSK-3 (1)

HDAC (7)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HSP (1)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

Ligands for Target Protein for PROTAC (2)

MAP4K (1)

MEK (3)

Mitochondrial Metabolism (1)

MMP (1)

Molecular Glues (1)

mTOR (65)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

PAK (1)

Paraptosis (1)

Parasite (1)

PARP (2)

PD-1/PD-L1 (1)

PERK (3)

Phosphatase (2)

PI3K (187)

PI4K (3)

PPAR (1)

PROTACs (4)

Ras (6)

Reactive Oxygen Species (ROS) (3)

Reference Standards (16)

SARS-CoV (1)

Syk (1)

VEGFR (1)

Virus Protease (1)

Wnt (1)

By Research Areas:

Cancer (185)

Cardiovascular Disease (1)

Infection (9)

Inflammation/Immunology (13)

Metabolic Disease (7)

Neurological Disease (9)

201

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-101562

Inavolisib 5+ Cited Publications GDC-0077; RG6114	PI3K Apoptosis	Cancer
Inavolisib (GDC-0077) is a potent, orally active, and selective *PI3Kα* inhibitor (IC₅₀=0.038 nM). Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer .

HY-10681

Gedatolisib 5 Publications Verification PKI-587; PF-05212384	PI3K mTOR	Cancer
Gedatolisib (PKI-587) is a highly potent dual inhibitor of *PI3Kα, PI3Kγ, and mTOR* with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

HY-156681

Tersolisib 1 Publications Verification STX-478; STX-478-101; LY4064809	PI3K	Cancer
STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective *PI3Kα* inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research .

HY-159852

BBO-10203	PI3K Ras Akt	Cancer
BBO-10203 is a potent inhibitor of *PI3Kα* and KRAS ^G12C, selectively and covalently binding to Cys242 in the RAS-Binding Domain of *PI3Kα, and inhibiting both the GTP-bound and GDP-bound states of KRAS ^G12C* with an IC₅₀ of 0.031 nM and an EC₅₀ of 0.02 nM. BBO-10203 disrupts the interaction between RAS isoforms and *PI3Kα, leading to the inhibition of RAS-mediated PI3Kα* activation, and reduces pERK expression, cell growth, and induces G₁ arrest and apoptosis. BBO-10203 can be used for the research of breast cancer, colorectal cancer, and non-small cell lung cancer .

HY-19962

Paxalisib 5 Publications Verification GDC-0084	PI3K mTOR	Cancer
Paxalisib (GDC-0084) is a brain penetrant inhibitor of *PI3K* and mTOR, with K_is of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively .

HY-15177

PF-04691502 10+ Cited Publications	PI3K mTOR Autophagy	Cancer
PF-04691502 is a potent and selective inhibitor of *PI3K* and mTOR. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with K_is of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-15174

Dactolisib Tosylate 65+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual *PI3K* and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-12046

PIK-93 5+ Cited Publications	PI4K PI3K Virus Protease	Cancer
PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC₅₀ of 19 nM, and also inhibits PI3Kγ and *PI3Kα* with IC₅₀ of 16 nM and 39 nM, respectively.

HY-174461

*PROTAC PI3Kα* degrader-1**	PROTACs PI3K	Cancer
PROTAC PI3Kα degrader-1 is a *PI3Kα* PROTAC degrader (DC₅₀ = 0.08 μM), demonstrating good selectivity for PI3Kα degradation over PI3Kβ, PI3Kγ, and PI3Kδ. PROTAC PI3Kα degrader-1 effectively degrades PI3Kα in a time- and concentration-dependent, over PI3Kβ, PI3Ky and PI3Kδ, and potently inhibited the phosphorylation of AKT at the Ser473site. PROTAC PI3Kα degrader-1 shows significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models. (Pink: PI3Kα ligand : (HY-174798), Blue: E3 ligase CRBN Ligand (HY-10984), Black: Linker, E3 ligase ligand-linker conjugate (HY-W940885)) .

HY-16596

CNX-1351	PI3K	Cancer
CNX-1351 is a potent and isoform-selective targeted covalent *PI3Kα* inhibitor with IC₅₀ of 6.8 nM.

HY-10683

PKI-402 10+ Cited Publications	PI3K mTOR	Cancer
PKI-402 is a selective, reversible, ATP-competitive inhibitor of *PI3K, including PI3K-α* mutants, and mTOR (IC₅₀=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).

HY-101146

SF2523 2 Publications Verification	PI3K Epigenetic Reader Domain DNA-PK	Cancer
SF2523 is a highly selective and potent inhibitor of *PI3K* with IC₅₀s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for *PI3Kα, PI3Kγ, DNA-PK*, BRD4 and mTOR, respectively.

HY-16526

Pilaralisib 5 Publications Verification XL-147; SAR245408	PI3K	Cancer
Pilaralisib (XL147; SAR245408) is a potent and highly selective class I *PI3Ks inhibitor with IC₅₀s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3K*δ.

HY-100385

Brevianamide F 2 Publications Verification Cyclo(L-Pro-L-Trp)	PI3K Bacterial	Infection
Brevianamide F (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity. Brevianamide F shows potent *PI3Kα* inhibitory activity with an IC₅₀ of 4.8 μM .

HY-143275

HL-8	PROTACs PI3K Akt	Cancer
HL-8 is a *PI3Kα* PROTAC degrader. HL-8 promotes the ubiquitination and degradation of PI3Kα. HL-8 reduces pAKT levels. HL-8 has anticancer activity against colon and cervical cancer (Pink: PI3Kα ligand (HY-143277); Blue: E3 ligase VHL ligand (HY-138678); Black: linker (HY-W002042)) .

HY-W1126235

DS02312223 D223	Molecular Glues Ras PI3K GLUT	Metabolic Disease
DS02312223 (D223) is a molecular glue that promotes the binding of RAS to *PI3Kα, with a K_d* of 0.76 μM for p110α. DS02312223 increases the binding affinity between GTP-bound KRAS (KRAS-GMPPNP) and p110α by nearly three orders of magnitude (K_D = 0.017 μM). DS02312223 stimulates the translocation of GLUT4 to the plasma membrane. DS02312223 promotes glucose uptake in the absence of insulin. DS02312223 can be used in diabetes research .

HY-15466

Izorlisib 3 Publications Verification CH5132799	PI3K	Cancer
Izorlisib (CH5132799) is a selective class I *PI3K* inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC₅₀ of 14 nM.

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective *PI3Kα* inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for *PI3Kα* and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-13440

AMG 511 5 Publications Verification	PI3K	Cancer
AMG 511 is a potent and orally available pan inhibitor of class I *PI3Ks, with K_is of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K* signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model .

HY-101272

GDC-0326 1 Publications Verification	PI3K	Cancer
GDC-0326 is a potent and selective *PI3Kα* inhibitor with a K_i of 0.2 nM.

HY-12869

AZD-8835 1 Publications Verification	PI3K	Cancer
AZD8835 is a potent and selective inhibitor of *PI3Kα* and PI3Kδ with IC₅₀s of 6.2 and 5.7 nM, respectively.

HY-13333

NVP-BAG956 BAG 956	PI3K	Cancer
NVP-BAG956 is an ATP-competitive *PI3K* inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-107365

PQR530	PI3K mTOR	Cancer
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar K_d toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity .

HY-15271

WYE-687 3 Publications Verification	mTOR PI3K	Cancer
WYE-687 is an ATP-competitive mTOR inhibitor with an IC₅₀ of 7 nM. WYE-687 concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits *PI3Kα* and PI3Kγ with IC₅₀s of 81 nM and 3.11 μM, respectively.

HY-118712

WYE-23	mTOR	Cancer
WYE-23 is a mTOR inhibitor, and IC₅₀ is 0.45 nM. It is selective to PI3Kα and IC₅₀ is 661 nM. WYE-23 has antitumor activity .

HY-B1550

Benzoin DL-Benzoin; Desyl alcohol; (±)-2-Hydroxy-2-phenylacetophenone	PI3K	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Benzoin (DL-Benzoin) is a *PI3Kα* inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116) .

HY-143404

PI3K-IN-30 3 Publications Verification	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .

HY-13864

PF-4989216 1 Publications Verification	PI3K Apoptosis	Cancer
PF-4989216 is a potent and selective *PI3Kα* inhibitor with a K_i of 0.6 nM.

HY-174798

PI3Kα Ligand-1	PI3K Ligands for Target Protein for PROTAC	Cancer
PI3Kα Ligand-1 is the ligand for PI3Kα that can be used for synthesis of PROTACs, such as PI3Kα degrader-1 (HY-174461) .

HY-12340

ETP-46321	PI3K	Cancer
ETP-46321 is a potent and orally bioavailable *PI3Kα* and PI3Kδ inhibitor with K_iapps of 2.3 and 14.2 nM, respectively.

HY-150618

PI3Kα-IN-9 1 Publications Verification	PI3K Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with IC₅₀ values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively. PI3Kα-IN-9 has antiproliferative activity and induces apoptosis. PI3Kα-IN-9 can be used for cancer research .

HY-124036

DS-7423	PI3K mTOR	Cancer
DS-7423 is a dual *PI3K* and mTOR inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity .

HY-136198

SRX3207	Syk PI3K	Cancer
SRX3207 is an orally active and first-in-class dual *Syk/PI3K* inhibitor, with IC₅₀ values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression .

HY-131345

PI3Kα-IN-4	PI3K	Cancer
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of *PI3Kα, with an IC₅₀* of 1.8 nM. PI3Kα-IN-4 has antitumor activity .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-156681A

(S)-Tersolisib (S)-STX-478; (S)-STX-478-101; (S)-LY4064809	PI3K	Cancer
(S)-STX-478 is the S-enantiomer of STX-478. STX-478 is a selective inhibitor of *PI3Kα* mutants, preventing metabolic dysfunction and demonstrating antitumor activity in xenograft mouse models with *PI3Kα* mutant tumors .

HY-100470

NSC781406 2 Publications Verification	PI3K mTOR	Cancer
NSC781406 is a highly potent *PI3K* and mTOR inhibitor with an IC₅₀ of 2 nM for PI3Kα.

HY-128333

PI3K/mTOR Inhibitor-4	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-10812

GNE-490	PI3K mTOR	Cancer
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model .

HY-11105

Pilaralisib analogue 1 Publications Verification XL147 analogue	PI3K Apoptosis	Cancer
Pilaralisib analogue (XL147 analogue) is a representative and selective *PI3Kα* inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.

HY-131345A

*(S)-PI3Kα-IN-4*	PI3K	Cancer
(S)-PI3Kα-IN-4 is a potent inhibitor of *PI3Kα, with an IC₅₀* of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer .

HY-143403

PI3K-IN-31	PI3K	Cancer
PI3K-IN-31 (Compound 6b) is a potent *PI3K* inhibitor with IC₅₀s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for *PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31* has anticancer effects .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for *PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR*, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-176281

PI3Kα-IN-26	PI3K CDK	Cancer
PI3Kα-IN-26 (Compound 11e) is a *PI3Kα* inhibitor with an IC₅₀ of 75.31 nM. PI3Kα-IN-26 has a broad-spectrum anticancer activity, such as leukemia, colon and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC₅₀s of 2.74, 3.50, 3.34 and 85.29 μM, respectively) .

HY-147767

PI3Kα-IN-6	PI3K Apoptosis Reactive Oxygen Species (ROS)	Cancer
PI3Kα-IN-6 (Compound 5b) is a *PI3Kα* inhibitor. PI3Kα-IN-6 exhibits anticancer potential and no toxicity in normal cells. PI3Kα-IN-6 increases generation of ROS, reduces mitochondrial membrane potential (MMP) and induces apoptosis .

HY-160458

PI3Kα-IN-17	PI3K	Others
PI3Kα-IN-17 (example 4) is a potent inhibitor of *PI3K*α .

HY-116563

PI3Kα-IN-24	PI3K	Cancer
PI3Kα-IN-24 (WR23) is a *PI3Kα* inhibitor with an IC₅₀ of 0.025 μM and exhibits a significant pAkt ^Ser473 suppression effect. PI3Kα-IN-24 can be utilized in cancer research .

HY-161140

PI3Kα-IN-16	PI3K Wnt	Cancer
PI3Kα-IN-16 (Z86) is a novel *PI3Kα* inhibitor with an IC₅₀ value of 4.28 μM. PI3Kα-IN-16 has potent inhibitory efficiency on PI3K-mediated CRCs growth and migration. PI3Kα-IN-16 also inhibits the Wnt signaling pathway .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a *PI3Kα* inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

Cat. No.	상품명	Type

HY-15244G

Alpelisib

Fluorescent Dyes

Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome ^[3] .

Cat. No.	상품명	Type

HY-15244G

Alpelisib

Biochemical Assay Reagents

Cat. No.	상품명	Category	Target	Chemical Structure

HY-100385

Brevianamide F 2 Publications Verification Cyclo(L-Pro-L-Trp)	Infection Alkaloids Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Endogenous metabolite Disease Research Fields Indole Alkaloids Source Classification	PI3K Bacterial
Brevianamide F (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity. Brevianamide F shows potent *PI3Kα* inhibitory activity with an IC₅₀ of 4.8 μM .

HY-B1550

Benzoin DL-Benzoin; Desyl alcohol; (±)-2-Hydroxy-2-phenylacetophenone	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	PI3K
Benzoin (DL-Benzoin) is a *PI3Kα* inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116) .

HY-B1550R

Benzoin (Standard) DL-Benzoin (Standard); Desyl alcohol (Standard); (±)-2-Hydroxy-2-phenylacetophenone (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards PI3K
Benzoin (Standard) (DL-Benzoin (Standard)) is the analytical standard of Benzoin (HY-B1550). This product is intended for research and analytical applications. Benzoin (DL-Benzoin), a natural balsamic resin, is a *PI3Kα* inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116). Benzoin can be used as a food additive.

HY-100385R

Brevianamide F (Standard) Cyclo(L-Pro-L-Trp) (Standard)	Alkaloids Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Indole Alkaloids Source Classification	Reference Standards PI3K Bacterial
Rebaudioside C (Standard) is the analytical standard of Rebaudioside C. This product is intended for research and analytical applications. Rebaudioside C (Dulcoside B) is a natural sweetener that can be used in controlled diets for diabetic patients.

Cat. No.	상품명	Chemical Structure

HY-B1550S

Benzoin-d10
Benzoin-d₁₀ (DL-Benzoin-d₁₀) is the deuterium labeled Benzoin (HY-B1550). Benzoin (DL-Benzoin), a natural balsamic resin, is a *PI3Kα* inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116). Benzoin can be used as a food additive .

HY-10681S

Gedatolisib-d8
Gedatolisib-d₈ (PKI-587-d₈) is the deuterium labeled Gedatolisib (HY-10681). Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC₅₀s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-15244G

Alpelisib	PI3K Apoptosis	Cancer
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to *PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch* and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome ^[3] .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

PI3Kα

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products